CN1742747A - Anti-cold nasal administration composition - Google Patents
Anti-cold nasal administration composition Download PDFInfo
- Publication number
- CN1742747A CN1742747A CN 200510010886 CN200510010886A CN1742747A CN 1742747 A CN1742747 A CN 1742747A CN 200510010886 CN200510010886 CN 200510010886 CN 200510010886 A CN200510010886 A CN 200510010886A CN 1742747 A CN1742747 A CN 1742747A
- Authority
- CN
- China
- Prior art keywords
- cold
- nasal administration
- administration composition
- nasal
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a nasal medication composition for relieving common cold symptom and inhibiting common cold virus. Said composite is made up by using (by wt%) 0.1%-60% of pseudoephedrine hydrochloride, 0.2%-30% of chlorphenamine and 0.1%-75% of ribavirin.
Description
Technical field
The present invention relates to a kind of alleviation cold symptoms, suppress the anti-cold nasal administration composition of cold virus.
Background technology
Flu is a kind of commonly encountered diseases and frequently-occurring disease, is divided into viral influenza and bacillary flu traditionally.Most clinically cases are viral influenza, mainly show as symptoms such as sneeze, nasal obstruction, rhinorrhea, dry pharynx; Or with general symptoms such as headache, unable, the inappetence of aching all over, heating, fear of cold.Therefore research and develop a determined curative effect, flu new drug easy to use, good market prospect.
Based on the characteristic of flu, main treatment function of the present invention is to alleviate cold symptoms, as nasal obstruction, rhinorrhea, sneeze; Suppress cold virus.
Flu is a kind of common disease, no matter is child, adult, or the old people, all is Susceptible population.But the following shortcoming of ubiquity:
1. most drug oral after, through the gastrointestinal tract enzymolysis, the liver first pass metabolism causes drug effect slow.
2. only be based on alleviating cold symptoms, take stopgap measures to overweight and effect a permanent cure.
3. most coldrexs are because the defective of dosage form, after taking generally with dry pharynx, untoward reaction such as thirsty, drowsiness.
The present invention adopts symptoms such as nasal obstruction after pseudoephedrine hydrochloride and chlorphenamine maleate are alleviated flu, rhinorrhea, sneeze, and therapeutic effect is definite.Because cold virus mainly attacks nasal mucosa and nasopharyngeal epithelial cell, adopt broad-spectrum antiviral drug ribavirin nasal-cavity administration in the invention, can make medicine go directly nose, nasopharynx part mucomembranous surface, suppress viral rapidly enduringly, reach treating both the principal and secondary aspects of a disease.
Consider lesions position mainly at nasopharynx part, virus main invasion and attack nasal mucosa and nasopharyngeal epithelial cell so nasal-cavity administration is adopted in decision, can make the medicine focus of go directly, bring into play curative effect rapidly, symptoms such as the nasal obstruction after alleviation is caught a cold, rhinorrhea, sneeze; Suppress cold virus.
Summary of the invention
The objective of the invention is to propose a kind of be used to alleviate cold symptoms such as nasal obstruction, rhinorrhea, sneeze etc.; Suppress the nasal administration composition of cold virus, the medicament made from said composition can make medicine directly act on the affected part, and drug absorption is lasting rapidly, convenient drug administration and bioavailability height, effectively control cold symptoms in the short period of time, shorten the course of disease, speedy recovery to health.
The anti-cold nasal compositions that the present invention relates to, it is characterized in that containing weight ratio is 0.1%-60% pseudoephedrine hydrochloride, 0.2%-30% chlorphenamine, 0.1%-75% ribavirin.
The anti-cold nasal compositions that the present invention relates to, it is characterized in that containing weight ratio is levofloxacin 0.1%-60%.
The anti-cold nasal administration composition that the present invention relates to, its antiviral agents ribavirin can substitute for one or more of Radix Isatidis, Flos Lonicerae, Fructus Forsythiae, tea polyphenols, Radix Scutellariae, baicalin, noroxylin, amantadine, rimantadine, Oseltamivir, Zha Namiwei.
Anti-cold nasal compositions medicament of the present invention is characterized in that it can being said dosage form on the pharmaceuticss such as gel, spray, aerosol, nasal drop, ointment, ointment, membrane, powder agent or all kinds of microparticle formulations.
The present invention is mainly used in alleviates cold symptoms, inhibition cold virus.
Good effect of the present invention has provided a kind of anti-cold nasal administration composition of being made up of pseudoephedrine hydrochloride, chlorphenamine, ribavirin.Its medicament can make medicine directly act on the affected part, and convenient drug administration can avoid pipe intestinal digesting enzyme and liver first pass metabolism to the destruction of medicine, has improved bioavailability, makes medicine absorb the performance curative effect rapidly.
Pharmacological evaluation is as follows:
Alleviate the cold symptoms experiment: this product can be shunk the thin blood vessel of vibrissa, eliminates the congested swelling of nasopharynx part, alleviates the nasal cavity edema, thereby suppresses the nasal mucus secretion and improve nasal obstruction, increases ventilation.
The antiviral experiment: this product can suppress multiple viruses such as influenza virus, parainfluenza virus, rhinovirus, respiratory syncytial virus virus.According to experiment, influenza virus selects for use another name for Sichuan Province to prevent-296 strains (H3N2), and cultural method adopts the cultivation in the chick embryo of influenza virus classics, and cultivation results adopts hemagglutination test to identify.Experimental result shows that said preparation resisiting influenza virus effect is better.
Clinical trial: this product adopts the clinical observation material of nasal-cavity administration:
1. case is originated: the object of observation is for being diagnosed as the common cold patient, and totally 100 examples all have cold symptoms such as nasal obstruction, watery nasal discharge, sneeze and headache in various degree, male 60 people, women 40 people.
2. using method: this product is coated with (spray) nose, each 0.2-0.5g, every day 3-5 time.
3. observed result: the person of throwing off a cold, the shortest 1d of treatment time, the longest 4d, effective percentage be more than 87.5%, very fast controlling symptoms after the medication, treatment more early, curative effect is high more.
The specific embodiment
Embodiment 1
Take by weighing 0.5g EDTA-2Na, the 2g benzalkonium bromide is soluble in water, 10g Ka Baibo is dissolved in the above-mentioned solution, fully swelling is standby, in addition 10g pseudoephedrine hydrochloride, 2g chlorphenamine, 10g ribavirin is dissolved in an amount of water, joins mix homogeneously among the above-mentioned Ka Baibo, constantly stir and add the 10g triethanolamine down, transfer between the pH to 6.5-7.5, add moisturizing at last, promptly get the clear gel agent to 1000g, be sub-packed in immediately in the container of airtight, lucifuge, store in Liang Chu.
Embodiment 2
Get the 1g chlorobutanol and be dissolved in an amount of distilled water, adding 20g pseudoephedrine hydrochloride, 5g chlorphenamine, 30g ribavirin, 5g sodium chloride, 5g levofloxacin make dissolving, mend the mix homogeneously to 1000g with distilled water, filter, and mixing, nasal drop is made in packing.
Embodiment 3
Get an amount of distilled water, stirring and dissolving 30g pseudoephedrine hydrochloride, 10g chlorphenamine, 20g amantadine, 5g sodium chloride, add 20g glycerol, 1g chlorobutanol at last, stir evenly, be mixed with certain density medicinal liquid, filter, adding distil water is to 1000g, stir evenly, transfer between the pH to 6.5-7.5, be sub-packed in the miniature nasal spray plastic bottle and promptly get the nose aerosol.
Embodiment 4
Get an amount of distilled water, add 50g pseudoephedrine hydrochloride, 6g chlorphenamine, 10g ribavirin, 5g sodium chloride and make dissolving, add 20g glycerol, 1g chlorobutanol at last, stir evenly, be mixed with certain density medicinal liquid, filter, adding distil water stirs evenly to 1000g, transfers between the pH to 6.5-7.5, and adding a certain amount of propellant, fill promptly gets nasal spray in pressure vessel.
Claims (5)
1. an anti-cold nasal administration composition is characterized in that the medicament of being made by the following weight proportion raw material: 0.1%-60% pseudoephedrine hydrochloride, 0.2%-30% chlorphenamine, 0.1%-75% ribavirin.
2. anti-cold nasal administration composition according to claim 1 is characterized in that containing the levofloxacin of weight proportion 0.1%-60%.
3. anti-cold nasal administration composition according to claim 1 is characterized in that the antiviral agents ribavirin can substitute for one or more of Radix Isatidis, Flos Lonicerae, Fructus Forsythiae, tea polyphenols, Radix Scutellariae, baicalin, noroxylin, amantadine, rimantadine, Oseltamivir, Zha Namiwei.
4. anti-cold nasal administration composition according to claim 1 is characterized in that medicament can be gel, spray, aerosol, nasal drop, ointment, ointment, membrane, powder agent or all kinds of microparticle formulation.
5. anti-cold nasal administration composition according to claim 1 is characterized in that being used to alleviate cold symptoms, suppressing cold virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010886 CN1742747A (en) | 2005-06-30 | 2005-06-30 | Anti-cold nasal administration composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010886 CN1742747A (en) | 2005-06-30 | 2005-06-30 | Anti-cold nasal administration composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1742747A true CN1742747A (en) | 2006-03-08 |
Family
ID=36138372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510010886 Pending CN1742747A (en) | 2005-06-30 | 2005-06-30 | Anti-cold nasal administration composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1742747A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619157A (en) * | 2018-07-25 | 2018-10-09 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules |
| CN115721726A (en) * | 2022-07-27 | 2023-03-03 | 江苏长泰药业有限公司 | Nasal cavity product for preventing or relieving cold symptoms and preparation method thereof |
-
2005
- 2005-06-30 CN CN 200510010886 patent/CN1742747A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619157A (en) * | 2018-07-25 | 2018-10-09 | 江苏黄河药业股份有限公司 | A kind of Levofloxacin Hydrochloride Capsules |
| CN115721726A (en) * | 2022-07-27 | 2023-03-03 | 江苏长泰药业有限公司 | Nasal cavity product for preventing or relieving cold symptoms and preparation method thereof |
| CN115721726B (en) * | 2022-07-27 | 2023-10-17 | 江苏长泰药业股份有限公司 | Nasal product for preventing or relieving cold symptoms and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021203614A1 (en) | Pharmaceutical composition for treatment of coronavirus diseases and preparation method therefor and application thereof | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| CN105727144A (en) | Traditional Chinese medicine composition for treating bronchitis and preparation method thereof | |
| CN102641356B (en) | Traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and preparation method thereof | |
| CN101991694A (en) | Application of traditional Chinese medical composition in preparation of medicament for resisting influenza A H1N1 influenza viruses | |
| CN102657804B (en) | Traditional Chinese medical composition for treatment of viral influenza and preparation method thereof | |
| CN104689173B (en) | A kind of compound Chinese medicinal preparation for treating gout | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
| CN1742747A (en) | Anti-cold nasal administration composition | |
| WO2011143844A1 (en) | Traditional chinese medicine composition for treating infection of influenza a virus subtype and preparation method thereof | |
| CN111991543A (en) | Traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and preparation method thereof | |
| CN101934032B (en) | Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof | |
| WO2014190555A1 (en) | Traditional chinese medicine composition for resisting influenza a virus infection and relieving cough, and preparation method therefor | |
| CN102188574B (en) | One treats bronchitic Chinese medicine composition of influenza A virus and preparation method thereof | |
| WO2011130892A1 (en) | Traditional chinese medicinal composition for treating influenza and preparation method and use thereof | |
| CN115919963A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating novel coronavirus infection | |
| CN105213353A (en) | Compound oral membrane containing Sodium Azulenesulfonate and preparation method | |
| CN1634479A (en) | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof | |
| CN1966051B (en) | Antivirus medicament for resisting virus | |
| CN107773695A (en) | A kind of Chinese medicine for being used to treat flat wart | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| WO2012075646A1 (en) | Traditional chinese medicine composition for treating infection of influenza a virus subtype and preparation method thereof | |
| CN101313937A (en) | Chinese medicinal composition for treating influenza virus type A upper respiratory tract infection and preparation method thereof | |
| CN101693058B (en) | Medicament for preventing and treating cold and inflammation infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |